News

09.01.2018

"We're giving Basel Impact Hub fever"

Impact Hubs are a real success story. Founded in 2005 in London, there are now over 100 Impact Hubs around the world with more than 15,000 members. Following the lead from Bern, Zurich, Geneva and Lausanne, Basel will be the next Impact Hub in Switzerland. The force behind the movement is Hubbasel, an association founded by entrepreneur André Moeri, sustainability expert Connie Low and lawyer Hanna Byland. We wanted to know why an Impact Hub is more than just a coworking space and how entrepreneurs as well as investors and companies benefit from them, so we talked with Hanna Byland to shed some light for us.

mehr >
22.01.2018

Basel – a welcoming city for expatriates

Basel – a welcoming city for expatriates

I am proud of my hometown Basel. Having travelled extensively, I value the benefits of living in a friendly, beautiful, and multi-cultural city.

mehr >
22.01.2018

uptownBasel – the first state-of-the-art Industry 4.0 campus in Switzerland

uptownBasel – the first state-of-the-art Industry 4.0 campus in Switzerland

In Arlesheim (Canton Basel-Land) just south of the city of Basel, uptownBasel AG is developing Switzerland's first Industry 4.0 campus. The site covers 70,000 square metres, has 750 parking spaces, and a direct motorway connection. Buses and trams also stop right at the doorstep. This all means the campus is ideally positioned to transform itself into a magnet for high-tech businesses over the coming years.

mehr >
04.12.2017

“Precision medicine is the best opportunity to reconfigure healthcare”

“Precision medicine is the best opportunity to reconfigure healthcare”

After 20 years with the pharmaceutical company Eli Lilly, Bernard Munos set out to better understand pharmaceutical innovation – specifically what makes it possible and how to get more of it. Munos is now a Senior Fellow at Faster Cures, a Center of the Milken Institute, and the founder of the consultancy InnoThink, which advises biomedical research organizations on how to become better innovators. He also contributes to Forbes magazine, an American business publication. Munos travelled to Basel in October, on behalf of HKBB and DayOne to participate in the “Powertalk”.

mehr >
22.01.2018

The Digital Evolution in Biotech and Pharma – BaselArea.swiss at JPM18

The Digital Evolution in Biotech and Pharma – BaselArea.swiss at JPM18

Basel evolved from a silk dyeing industry hub in the 18th century to a chemical to a life sciences hub. What’s next?

mehr >
19.01.2018

Clariant strengthens international market position

Clariant strengthens international market position

Specialty chemicals company Clariant has opened a new production site in Saudi Arabia, where it will produce masterbatches. It is also increasing production capacity in Mexico.

mehr >
06.11.2017

“We want to improve the visibility of startups at the University of Basel”

“We want to improve the visibility of startups at the University of Basel”

Christian Elias Schneider has been Head of Innovation at the University of Basel for eight months now. His job is to promote entrepreneurship and projects in collaboration with industry.

mehr >
18.01.2018

Novartis subsidiary developing novel biosimilars

Novartis subsidiary developing novel biosimilars

Pharmaceutical company Sandoz has entered into a partnership with Indian biopharmaceutical Biocon to develop biosimilars for use in immunology and oncology.

mehr >
18.01.2018

Roivant Sciences to join BaseLaunch Accelerator as Healthcare Partner

Roivant Sciences to join BaseLaunch Accelerator as Healthcare Partner

Roivant becomes the fifth healthcare partner of BaselArea.swiss accelerator program joining Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer and Roche.

mehr >
03.10.2017

"You should always have something crazy cooking on the back burner"

When Jennifer Doudna gave her keynote at Basel Life in September, the auditorium in the Congress Center was packed. Susan Gasser, Professor of Molecular Biology at the University of Basel introduced Doudna as groundbreaking and extremely innovative. The Professor of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley was on top of Gassers wish list for the Basel Life. The leading figure of what is known as the CRISPR revolution among scientists sat down with BaselArea.swiss during her stay in Basel to talk about her lab, flexible career paths and what makes a great researcher.

mehr >
16.01.2018

Basel railway junction should be expanded further

Basel railway junction should be expanded further

The Basel Chamber of Commerce feels that the Federal Council’s proposal on expanding rail capacity does not give sufficient weight to the importance of Basel’s railway junction. It considers a complete expansion of the railway junction and the assumption of costs as minimum requirements.

mehr >
15.01.2018

Viollier: Innovation und Sicherheit im vernetzten Gesundheitswesen

Viollier: Innovation und Sicherheit im vernetzten Gesundheitswesen

Das labormedizinische Unternehmen Viollier setzt voll auf digitale Innovation, um sich am Markt zu differenzieren. Um die Sicherheit der hochsensiblen medizinischen Daten zu garantieren, kooperiert das Unternehmen mit dem Berner Sicherheitsspezialisten United Security Providers. Unter anderem können Arztpraxen oder Spitäler so heute papierlos 24/7 Laboruntersuchungen (z. B. Blut oder Gewebe) direkt im Webportal von Viollier verordnen. 

mehr >
29.09.2017

Spirochem opens new state-­of-­the-­art Services and R&D facilities in Basel

Spirochem opens new state-­of-­the-­art Services and R&D facilities in Basel

Basel – The fine chemicals company SpiroChem has relocated to state-of-the-art facilities in the Rosental area of Basel, offering the company an ideal location to significantly expand its operations. SpiroChem has also strengthened its board of directors.

mehr >
12.01.2018

Genedata launches new solution for CRISPR experiments

Genedata launches new solution for CRISPR experiments

Basel-based software firm Genedata has launched a new solution for data management and analysis of CRISPR experiments. Currently available software tools have been insufficient until now.

mehr >
12.01.2018

Basel - Weltstadt im Taschenformat

Basel ist die Stadt der kurzen Wege: vom Euroairport gehts zum Messeplatz, vom Zoo in die St. Jakobshalle ans Tennismatch mit Roger Federer. Hochkarätige Museen finden sich an jeder Ecke und Architektur auf Weltklasseniveau begegnet man auf Schritt und Tritt. So präsentiert sich Basel im neuen, knapp fünfminütigen Imagefilm.

mehr >
18.09.2017

13 startup projects qualify for the first phase of BaseLaunch

13 startup projects qualify for the first phase of BaseLaunch

The BaseLaunch Healthcare Accelerator program from BaselArea.swiss started on September 14. Over 100 applications were received from more than 30 countries, and the selection committee has selected 13 projects to go on to Phase I. Now, the project teams will work with industry experts to further develop their business case over the next three months.

mehr >
11.01.2018

Novartis appoints new oncology head

Novartis appoints new oncology head

On February 1, Elizabeth Barrett will succeed to the role of head of oncology at the Basel-based pharmaceutical giant Novartis. She is currently Pfizer’s Global President Oncology.

mehr >
09.01.2018

The Services of the Jura "Economy and Employment Department" are on their way to Digitization

The Services of the Jura

The Economy and Employment Department (SEE), a result of the merging of the Economy Department and the Arts & Employment Department, came into effect on June 1, 2015. It moved on a single site in October 2017, located in Delémont. A pioneering step but only a “first step”, according to the head of this new department Claude-Henri Schaller, who aims to digitize the processes and services offered, with an interactive online offer, in a pilot approach within the Jura cantonal administration. In the following interview, he reveals his action plan with the challenges that such a transformation represents, but also an optimistic vision shared by his entire team.

mehr >
05.09.2017

"In Switzerland, we often sell promising technologies too early"

Ulf Claesson is a "serial entrepreneur". During the past 25 years, he has set up companies that have gone on to become firmly established in the market. In 2012, he joined Clinerion as CEO and shareholder. Since then, the company has positioned itself in the medical data field and recently entered into a partnership with British company Cisiv. Clinerion's software helps recruit patients for clinical trials run by major pharmaceutical companies – in real time. But the competition never sleeps. A growing number of competitors is now appearing, especially in the USA where there is no shortage of risk capital. In this interview for the Innovation Report, Claesson explains how the Basel-based healthtech company plans to maintain its leadership position.

mehr >
09.01.2018

Basel region creates more jobs

Basel region creates more jobs

In 2017, the number of available jobs rose throughout Switzerland when compared with the previous year. On account of its rapidly growing economy, the Canton of Basel-Stadt registered the strongest increase. Basel-Landschaft also stands out for its high level of job vacancies.

mehr >
09.01.2018

FutureHealth Basel: Focus on the patient

FutureHealth Basel: Focus on the patient

The complex, federal and highly regulated healthcare system is currently in a state of upheaval. Demographic trends as well as technological advancements place existing business models before large challenges - and with them so do all the various actors along the entire value chain of the healthcare industry. The modern healthcare system requires interdisciplinary and cross-sector solutions. For this reason, FutureHealth Basel is focussed not only on science and technology, but rather places the most fundamental component of all at its core: the patient and his or her needs.

mehr >
04.07.2017

"I want to turn innovative research into new drugs"

Cellestia CEO Michael Bauer.

Each year some 250,000 patients develop a type of cancer because of faulty communication between cells. This malfunction occurs in what is known as the NOTCH signal path. There are currently no effective treatments – but this is set to change. Cellestia Biotech AG is developing an innovative drug against this type of cancer by using a novel active ingredient that selectively attacks the malfunctioning cell communication. The drug could be used to treat leukaemia, lymphomas and solid tumours such as breast cancer.

mehr >
09.01.2018

The new FHNW Institute for Digital Construction is present at Swissbau

The new FHNW Institute for Digital Construction is present at Swissbau

The FHNW founded the new Institute for Digital Construction at the beginning of January 2018 in response to changes within the construction industry. The new institute and its nine employees will be headed by Professor Manfred Huber.

mehr >
08.01.2018

Roche and GE enter digital diagnostics partnership

Roche and GE enter digital diagnostics partnership

The Basel-based pharmaceutical giant Roche and the industrial corporation General Electric (GE) are partnering to develop a software. The aim is to support doctors treating cancer patients.

mehr >
13.06.2017

Roivant is creating a buzz in Basel

Roivant is creating a buzz in Basel

Roivant Sciences, a fast-growing life sciences company from the US, recently opened its global headquarters in Basel. In celebration of their newly established location, Roivant, together with BaselArea.swiss, invited stakeholders from the life sciences sector to “Halle 7, Gundeldingerfeld” in Basel on June 8th 2017 for a panel discussion on the future of healthcare.

mehr >
05.01.2018

Roche enters into research partnership

Roche enters into research partnership

The Basel-based pharmaceutical company Roche has entered into a research collaboration with the U.S. company MacroGenics to develop novel bispecific molecules for use in the treatment of cancer and other diseases.

mehr >
02.01.2018

Roche and Novartis among most valuable companies

Roche and Novartis among most valuable companies

The Basel pharmaceutical companies Roche and Novartis are among the 40 most valuable companies in the world, according to an EY study. American tech firms top the list.

mehr >
08.06.2017

BaselArea.swiss got off to a successful start

BaselArea.swiss got off to a successful start

In its first annual report, the newly formed BaselArea.swiss can look back on a successful 2016. The joint initiative for innovation and economic promotion by the cantons of Basel-Stadt, Basel-Landschaft and Jura succeeded in growing in all areas. It provided assistance to 36 companies moving to the region, which corresponds to a 50% increase over the previous year. In the area of innovation promotion, over 4,000 participants attended 80 events, expanding the regional network from 8,000 to 13,000 innovators and experts. The services provided by BaselArea.swiss were also actively used to promote start-up projects, contributing to 43 companies being founded.

mehr >
02.01.2018

Basel is more accessible

Basel is more accessible

Swiss cities are more accessible worldwide today than they were two years, as is shown in the current BAK Accessibility Index. Basel improved its accessibility within Europe in particular.

mehr >
22.12.2017

Basel scientists cool chip to record low

Scientists at the University of Basel have cooled a nanoelectronic chip to a temperature lower than 3 millikelvin. Cooling to this level will enable experiments that enhance the understanding of physics at close to absolute zero.

mehr >
08.06.2017

A molecular assembly line to cure the body

A molecular assembly line to cure the body

Imagine that certain forms of blindness could be cured. Or imagine that the body itself could produce a cure for some of its own diseases. These may be just some of the results of the National Centre of Competence in Research Molecular Systems Engineering (NCCR MSE). Its long-term goals are to create molecular systems and factories for the production of high added-value chemicals and develop cellular systems for new applications in medical diagnostics, therapy and treatment. Director Thomas Ward is aiming high: He wants to make Basel the leading hub for the next European flagship project. At stake: one billion euro.

mehr >
21.12.2017

Finding new models to keep us healthy

Finding new models to keep us healthy

The last DayOne Experts event of 2017 had over 90 participants who came to hear about disruption in healthcare insurance and both how it affects the Pharma industry and how together Pharma, Insurers and others can work to find a better model for all parties.

mehr >
21.12.2017

EuroAirport agreement will apply from early 2018

EuroAirport agreement will apply from early 2018

The agreement regulating the new tax regime at Basel-Mulhouse Airport will come into force at the start of next year. The Swiss and French foreign ministers agreed on its conclusion. The National Assembly formerly ratified the agreement.

mehr >
15.05.2017

Investing in strengths – Swiss leadership in life sciences

Investing in strengths – Swiss leadership in life sciences

How can Switzerland and the Basel region maintain their international leadership role in life sciences? As part of the Biotech and Digitization Day, Federal Councillor Johann Schneider-Ammann visited the Basel region to discuss current trends and challenges with a high-ranking delegation from politics, business, research and start-ups.

mehr >
20.12.2017

Idorsia teams up with Roche on research

Idorsia teams up with Roche on research

The research company Idorsia has entered into a research collaboration with Roche in the field of cancer immunotherapy. The two Basel-based companies plan to develop new compounds for treating cancer.

mehr >
19.12.2017

BC Platforms supports genome study

BC Platforms supports genome study

The data management company BC Platforms announced that it is cooperating with the FinnGEN programme. The Finnish study plans to examine hundreds of thousands of blood samples to deepen our understanding about the origins of diseases and their treatment.

mehr >
09.05.2017

The healthcare system must take responsibility

The healthcare system must take responsibility

Kristian Schneider wants to improve the quality of health care and better manage the rising healthcare costs by means of a network that includes doctors, hospitals, insurance companies and the state. Its aim is to provide exactly those services needed for the health of patients. For the canton of Jura, which like all other cantons suffers from the fragmentation of service providers, this could be a unique opportunity to build an integrative care system – and thus become a pioneer, says the director of Hôpital du Jura.

mehr >
18.12.2017

Discovered! Innovative Chemistry by companies and students in Basel

Discovered! Innovative Chemistry by companies and students in Basel

What happens when BaselArea.swiss, the Swiss Chemical Society and the two universities invite to a 5 hour event named “Wanted: Innovative Chemistry of Today, 2030 and Beyond”? A lot! About 90 people attended, 4 companies presented, 8 researchers pitched their projects within 3 minutes, 36 key topics and ideas were collected and intense discussions continued even during the extended apero.

mehr >
18.12.2017

Three future railway lines to EuroAirport

Three future railway lines to EuroAirport

Three railway lines will travel to EuroAirport beginning in the mid-2020s. The coordinated schedule agreed upon by authorities in Switzerland and France means that trains will depart from Basel to the airport every 10 minutes.

mehr >
21.04.2017

Basel-Landschaft welcomes new companies

Basel-Landschaft welcomes new companies

The canton of Basel-Landschaft welcomed a host of new companies over the past few weeks. BaselArea.swiss played in a big role in attracting the companies to establish themselves in Basel.

mehr >

 

(Source: http://www.baselarea.swiss/en/baselarea-swiss/channels/innovation-report.html)